NUVB News and Press, Nuvation Bio Inc. Class A From 08/11/22

Maraganore brings more than 35 years of scientific, research and development, capital markets and managerial leadership expertise to ProKidney Fox joins Board with more than 25 years of healthcare investment banking, finance and capital markets experience WINSTON-SALEM, N....

Dosing underway for Phase 1 monotherapy study of NUV-868 in advanced solid tumors Strong financial position provides cash runway through 2028; cash, cash equivalents and marketable securities of $703.8 million as of June 30, 2022 Nuvation Bio Inc. (NYSE: NUVB), a bio...

Nuvation Bio ( NYSE: NUVB ) said it is discontinuing the clinical development of NUV-422 and reducing its workforce by 35% to save cost and focus on other programs. The company said the decision to discontinue NUV-422 factored in feedback from the U.S. Food and Drug Admi...

Company prioritizes NUV-868, its BD2 selective BET inhibitor currently in a Phase 1 dose escalation study in advanced solid tumors, and its novel small molecule Drug-Drug Conjugate (DDC) platform Company restructuring and cost savings associated with NUV-422 program discontinu...

Dr. Liu is a clinical leader who brings expertise in the discovery, development, and regulatory approval of oncology therapies worldwide Ms. Wentworth has over two decades of industry experience in domestic and international regulatory and quality affairs Nuvation Bi...

A new 2022/23 study continues the trading studies from 2017 testing abnormal Russell Index reconstitution returns from scholarly literature. Since 2017 the best return results from a price momentum test generated +57.90% in the first six months and average gains reached +29.04% in the...

Borqs Technologies (BRQS) -25% after announcing 1-for-16 reverse stock split. Benitec Biopharma (BNTC) -13%. ToughBuilt Industries (TBLT) -14%. Chimerix (CMRX) -10% Monkeypox plays are lower as WHO rules out emergency status. Fujian Blue Hat Interactive Entertainment Techn...

Nuvation Bio (NYSE:NUVB) dropped ~14% in the pre-market Monday after the clinical-stage biopharmaceutical company announced that the FDA imposed a partial clinical hold on an early-stage trial for its lead candidate NUV-422 in cancer. The Phase 1 dose escalation study was designed t...

Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced the Food and Drug Administration (FDA) has placed a partial clinical hold on the Companyȁ...

David Abrams’ 13F portfolio value decreased this quarter from $4.56B to $4.28B. The number of positions remained steady at 18. Abrams Capital Management increased Coupang and Cantaloupe while reducing AMERCO during the quarter. The top three positions are Lithia Motors, Alp...